Articles by " Jeff Stewart"

No Thumbnail

Breast Implants: Dow Chemical or Corning will pay

When the corporate veil theory was used to insulate the parent companies from Dow Corning's liability, Verdict predicted that one of the parent companies would be held liable.

Aug 31, 1997
Read More
No Thumbnail

Bromide Investigation

September 18, 2000 In its June 17, 1999 article discussing Great Lakes Chemical’s cooperation with the Justice Department investigation,  Verdict [...]

Sep 9, 2000
Read More
No Thumbnail

BuSpar: Will FDA list BMY new Buspar patent ?

December 4, 2000 Bristol Myers Squibb submitted  a new patent, (’365), (which it claims covers BuSpar), to the FDA for [...]

Dec 4, 2000
Read More
No Thumbnail

Canadian Income Trusts: Tax Likely to Pass Soon

June 5, 2007 Summary: In May, Verdict for Investors predicted that Bill C- 54 (the Canadian Budget implementation bill taxing [...]

Jun 5, 2007
Read More
No Thumbnail

CANAL+ vs. NDS GROUP

April 15, 2002 On March 11, 2002, Canal+, a French media company sued NDS, its U.K. competitor, in a San [...]

Apr 15, 2002
Read More
No Thumbnail

Claritin 1: Judge likely to deny Summary Judgment

June 26, 2002 Introduction. On June 25, 2002, a federal judge in Newark[1] heard oral arguments on the validity of [...]

Jun 26, 2002
Read More
No Thumbnail

Claritin 2: Schering Plough loses Claritin Patent Protection

August 9, 2002 By GARDINER HARRIS Staff Reporter of THE WALL STREET JOURNAL A federal judge threw out Schering-Plough Corp.’s [...]

Aug 9, 2002
Read More
No Thumbnail

Columbia/HCA 1: Healthcare Corporation

The following outline suggests that Columbia’s troubles are more threatening than the ones at ADM.  In addition, healthcare fraud has [...]

Aug 31, 1997
Read More
No Thumbnail

Columbia/HCA 2: Settlement Talk Rumors

Rumors of settlement talks are circulating.  One billion dollars is the range being rumored. Unfortunately, investigations of reliable sources have [...]

Feb 25, 1999
Read More
No Thumbnail

Columbia/HCA 3: Jury Hears Criminal Fraud Evidence

Columbia/HCA stock has risen to the $26 – $28 range but two recent legal developments may lead to price reversals.  [...]

May 6, 1999
Read More